Sponsor or institution
Clinical trials and research at Wistar Institute
As of November 12, 2026, Find a Trial lists 144 NIH-funded research projects at this institution, with $110.1 million in listed awards. Every study is explained in plain English. Data from ClinicalTrials.gov and NIH RePORTER, updated November 12, 2026.
- 144NIH research projects
NIH-funded research (newest 40 of 144)
Early-stage science funded by the US National Institutes of Health. Most of these projects don't enroll patients, but they show what is being worked on.
-
Immunomodulation to Fight Cancer Spread
A cancer-focused training opportunity to learn how tumors and the immune system interact during cancer spread and use that knowledge to develop new immunotherapies.
-
Broadly neutralizing nanobodies to improve HIV therapy
Researchers are developing tiny antibodies called nanobodies to target HIV in new ways that could make treatments easier and more effective for people living with HIV.
-
BEAT-HIV: a collaborative effort to cure HIV with immunotherapy
A multi-institution study is testing a combination immunotherapy approach to achieve long-term HIV remission or cure for people on ART.
-
Epitope-engineered stem cells to enable HIV cure with targeted CAR-T therapy
A patient-focused plan to use a person’s own stem cells, edited to resist HIV and paired with specialized CAR-T cells, to clear HIV reservoirs.
-
Comprehensive bioinformatics support for cancer research at a leading cancer center
A cancer center-wide bioinformatics program helps researchers analyze data, build reusable data resources, and apply computational methods to cancer studies.
-
Refocusing HIV antibodies to target parts that block many strains
This project tries a new vaccine approach to steer the immune system to make antibodies that can block many types of HIV for people at risk.
-
Neutralizing IFN-I to boost HIV-targeted CAR T cell therapy
A new approach aims to block a specific immune signal (IFN-I) to help HIV-fighting CAR T cells work better in people living with HIV who are on ART.
-
Plasma biomarker clues to HIV reservoir activity in people on ART
Researchers will look for blood protein signals that relate to hidden HIV activity in people on antiretroviral therapy.
-
Proteomics and Metabolomics Resources to Fuel Cancer Research
A shared proteomics and metabolomics facility at leading cancer centers provides advanced analyses to support cancer research and other biomedical studies.
-
Rapid coronavirus vaccines using DNA-launched nanoparticles and adjuvants
A fast, one-dose vaccine approach using DNA-delivered, self-assembling nanoparticles designed to protect against current and future coronaviruses, including in older adults.
-
Broad nanovaccines to protect against diverse coronaviruses
A research grant aims to create nanoparticle vaccines that provoke broad protection against many coronaviruses by targeting shared receptor-binding sites.
-
Universal coronavirus vaccine program: next-generation nucleic acid vaccine development
A patient-focused big-picture grant aims to create a broad coronavirus vaccine using new delivery methods to protect people from current and future COVID-related viruses.
-
Universal coronavirus vaccine built with nanoparticle-delivered nucleic acids
A patient-focused vaccine project aims to create a broadly protective COVID-19 vaccine using cutting-edge DNA/RNA delivery inside tiny nanoparticles.
-
MEPCS vaccine to block SIV/HIV transmission in at-risk groups
A new vaccine approach uses a multi-epitope design to train the immune system to block HIV-like viruses at the point of exposure.
-
Pilot-Trans Network Core (PDTC/PDXNet)
A program that funds and guides new ideas within the PDTC and PDXNet to strengthen melanoma patient research networks and share findings with researchers.
-
Personalized targeting of cell-death pathways to overcome drug resistance in melanoma
A cancer research project aims to overcome treatment resistance in melanoma by targeting the proteins that keep tumor cells alive.
-
Precision therapies to overcome melanoma drug resistance
A large research effort is using patient tumor samples and animal-like models to find targeted treatments that help melanomas stop resisting therapy.
-
Bioinformatics Core for PDx Data and Analysis
A Bioinformatics Core at Wistar helps analyze and securely store complex cancer data so researchers can learn from many experiments and share results.
-
Melanoma PDX Resource Center for 3D Tumor Models
A melanoma-focused resource center provides living tumor models and 3D shapes to help researchers test new treatments.
-
Precision therapies for melanoma that work with patients’ tumors
A large, patient-focused effort uses tumor samples from people with melanoma to test and develop combination treatments that overcome resistance and extend responses.
-
One-dose DNA nanoparticle vaccines to protect against coronaviruses
This project develops single-dose, DNA-launched nanoparticle vaccines designed to give strong, long-lasting protection against COVID-19 and related coronaviruses, especially for older adults.
-
Nanoparticle vaccines designed to protect against many coronaviruses
This project aims to create nanoparticle vaccines that trigger broad protection against many coronaviruses for people at risk of COVID-19 and future coronavirus outbreaks.
-
Next-generation universal coronavirus vaccine using synthetic genetic material and nanoparticles
This program aims to create a new vaccine that could protect people against many different coronaviruses by using synthetic genetic material delivered in nanoparticles.
-
Universal coronavirus vaccine using nucleic-acid nanoparticles
A new vaccine approach uses tiny particles carrying genetic instructions to protect people against many different coronaviruses, including future variants.
-
How acetylcarnitine helps ovarian cancer resist chemotherapy
This project looks at whether lowering acetylcarnitine in high-grade serous ovarian cancer can make tumors more sensitive to standard DNA-damaging chemotherapy.
-
How metabolism and gene packaging drive cyclin E–high ovarian cancer
This work aims to find out whether blocking a cancer cell pathway that makes acetyl‑CoA-driven changes can help treatments like PARP inhibitors work better for people with cyclin E–high high‑grade serous ovarian cancer.
-
First-in-class Mdm2 PROTACs to treat cancers with mutant or missing p53
A new treatment approach uses Mdm2-targeting PROTACs to remove Mdm2 from cancer cells that lack functional p53, aiming to kill cancer cells and work in living organisms.
-
Reprogramming T cells to make safer, smarter CAR-T cancer therapy
A new NIH grant aims to make CAR-T cell therapy safer and more effective for solid cancers by letting engineered T cells tune themselves and by blocking the tumor’s immune-suppressing signals.
-
How Integrator and PP2A control transcription in human cells
A study to understand how a cellular machine called Integrator, together with PP2A, controls when RNA polymerase II pauses and resumes copying genetic information in human cells, and how disease-related PP2A changes affect this process.
-
Targeting immunosuppressive neutrophils to boost brain tumor therapies
This grant aims to uncover how a special group of neutrophils helps brain tumors like glioblastoma resist treatment and to identify ways to block those cells to improve therapies.
-
How ATRX and CTCF Shapes Brain Development
This NIH grant explores how changes in the ATRX gene affect brain cell development and the organization of the genome, which may help people with related developmental brain conditions.
-
Individualized HIV Cure Strategy using personalized antibodies and immune cells
This grant aims to tailor a combination immune therapy for people with HIV on antiretroviral therapy to help control or reduce the viral reservoir.
-
Functional analysis of p53 variants that are not fully active
Scientists are studying how specific p53 gene variants that still work somewhat could influence cancer risk, using findings to better understand why some people develop cancer earlier.
-
Nanobodies that target Lag3 to regulate inflammation and boost cancer immunotherapy
A fast-start research project to develop tiny antibodies (nanobodies) against Lag3 to help control inflammation and improve how the immune system fights cancer.
-
Parkin’s role in stopping cancer by boosting immune attack on tumors
This NIH grant studies how Parkin helps prevent cancer by making the immune system more aggressive against tumors.
-
Epigenetic control of KSHV latency in AIDS-related cancers
A scientist is studying how a herpesvirus that causes AIDS-related cancers stays latent and how this could be targeted to help patients.
-
Melanoma: understanding how melanoma cells change identity and resist therapy
Researchers are studying advanced melanoma to understand why some tumors stop responding to therapy and spread, aiming to find new ways to stop this by targeting how melanoma cells change their behavior.
-
Enhanced NK cell strategies to target HIV reservoirs
Aims to boost the body’s natural killer cells to better destroy HIV-infected cells during antiretroviral therapy using special antibodies and engineered immune cells.
-
Epstein-Barr virus–linked stomach and nasopharyngeal cancer models
Building and sharing lab-grown tumor models and animal models of EBV-positive stomach and throat cancers to speed development of better treatments for people with those cancers.
-
Targeted molecules that destroy cancer-driving proteins
Researchers are making new drug-like molecules that can find and break down proteins tied to Epstein-Barr virus–related cancers and other tumors.
Find the studies that fit you
A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.